Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Familiar Renal Disease, Epidemiology and Genetics in Niteroi/Rio de Janeiro (REGENT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03114852
Recruitment Status : Recruiting
First Posted : April 14, 2017
Last Update Posted : August 28, 2019
Sponsor:
Information provided by (Responsible Party):
Jorge R Almeida, MD, Universidade Federal Fluminense

Brief Summary:
The REGENT study (Familiar Renal Disease, Epidemiology and Genetics in Niteroi/Rio de Janeiro) is a epidemiological study that try to identify and clinically describe questions about genetic renal diseases in a southeast Brazilian population undergoing renal replacement therapy.

Condition or disease Intervention/treatment
Kidney Diseases Diagnostic Test: blood collection

Detailed Description:
In Brazil, several kidney diseases have unknown etiological diagnosis, among them, hereditary renal diseases. The lack of technical-scientific knowledge and patients' access to the health service hinder the correct diagnosis, so that hundreds of patients with chronic kidney disease (CKD) are unaware of the origin of their kidney problems. The objective of this REGENT study (Renal epidemiology and genetics in Niteroi) is to identify and characterize the cases of possible inheritance of CKD in patients undergoing dialysis or kidney transplant treatment in the metropolitan region II of the state of Rio de Janeiro. In this metropolitan region, based in the city of Niteroi, there are 10 hemodialysis clinics accounting for approximately 1500 - 1800 patients. There is a central Hospital that works as an official reference center for all those CKD patients (Hospital Universitario Antonio Pedro). This hospital belongs to the Universidade Federal Fluminense, an academic research institution, where this project will be executed. There is also a kidney transplant unit working at the Hospital Universitario Antonio Pedro. Interviews, sociodemographic and clinical data collection will be performed in patients with CKD from these centers. The interview contains questions about family CKD: Does any family member undergo hemodialysis or peritoneal dialysis? Does any family member do/did conservative treatment for CKD? Has any family member had a kidney transplant? Has any family member died due to chronic kidney disease? In cases of any affirmative answer to one of the above questions, patients will be classified as a "family index case". The cases of familial kidney disease caused by diabetes, and polycystic kidney disease will be excluded. So, the remaining cases will be considered as "index cases" to be more described and characterized. In this way, an affirmative response to the survey will create a group of familial CKD, and it will allow us to identify them as a suspected genetic kidney disease. These patients will be analyzed as a group, and clinical histories and blood tests to genetic renal diseases will also be performed, when possible, depending on the availability. From these identified index cases, we will try to create familiar clinical description of each individual in every family. A new outpatient section is being created at the Hospital Universitario Antonio Pedro to take multidisciplinary care of the relatives and entire families in a special type of family primary care.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1800 participants
Observational Model: Family-Based
Time Perspective: Prospective
Official Title: The REGENT Study: Familiar Renal Disease, Epidemiology and Genetics in Niteroi/Rio de Janeiro
Actual Study Start Date : March 20, 2017
Estimated Primary Completion Date : December 20, 2019
Estimated Study Completion Date : December 20, 2019

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
CKD patients

'blood collection'

Patients with chronic kidney disease in renal replacement therapy living in the sanitary administrative region of Niteroi/Rio de Janeiro. They will be interviewed about past history of familiar renal disease. They will have blood functional renal biochemistry analysed.

Diagnostic Test: blood collection
They will have blood tested to renal genetic diseases

Renal Familiar Disease
'blood collection' They will have blood tested to renal genetic diseases
Diagnostic Test: blood collection
They will have blood tested to renal genetic diseases




Primary Outcome Measures :
  1. Frequency and numbers of patients with renal familial diseases that are on renal replacement therapy in southeast Brazil. [ Time Frame: The familial epidemiological results will be ready up to 24 months form the start of the study. ]
    We will proceed a clinical interview using a questionnaire focused on the family history, among each Brazilian patients from dialysis or transplant center from the region of Niteroi/Rio de Janeiro. Patients with a positive history of familial disease will be included as a "case of familial renal disease". The results of the interviews will be analysed to create a report about incidence and prevalence of genetic renal disease among the southeast Brazilian people. At the same time we are creating a genetic reservoir to characterization of renal diseases in southeast of Brazil and we are also creating the basis to a cohort study based these families, through a new recently created outpatient unit to take care of familial renal diseases to follow all these involved renal families.


Secondary Outcome Measures :
  1. Frequency of uromodulin and APOL-1 mutation in southeast Brazilian patients underwent renal replacement therapy [ Time Frame: From the time to DNA extraction, by using molecular studies, the DNA samples of each index cases will be analyised to uromodulin and APOL1, up to 48 months. ]
    A complete mutation analysis, with identification of polimorphism SNPs to uromodulin and APOL-1 will be place as an initial specific protocol by using extracted DNA from the familial index cases.


Biospecimen Retention:   Samples With DNA
A blood collection of patients with familial history of renal disease will be done to extract DNA and to perform analysis of mutations and sequencing. After that, the samples will not be retained.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Months to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The population to be studied will be formed by southeast Brazilians that are on renal replacement therapy as dialysis or kidney transplantation. Such patients with renal diseases will answer a questionnaire about familial involvement. Some of them will be characterized as a familial index case of not yet determined genetic kidney disease.
Criteria

Inclusion Criteria:

  • Brazilian patients underwent any type of renal replacement therapy, dialysis or kidney transplantation living in the area of Niteroi/Rio de Janeiro.
  • Relatives among the familial people of the index cases.

Exclusion Criteria:

  • Diabetic Nephropathy
  • Non-familial cases of known Glomerulonephritis
  • Refuse in participating of interview and blood collection to genetic tests

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03114852


Contacts
Layout table for location contacts
Contact: Jorge R Almeida, MD, PhD +55 21 983747176 jorgereis@id.uff.br
Contact: Cinthia C Abreu, MSc +55 21 985468018 cinthia_costa@id.uff.br

Locations
Layout table for location information
Brazil
Universidade Federal Fluminense Recruiting
Niteroi, RIO DE Janeiro, Brazil, 24033900
Contact: Jorge R Almeida, MD, PhD    +55 983747176    jorgereis@id.uff.br   
Sponsors and Collaborators
Universidade Federal Fluminense
Investigators
Layout table for investigator information
Principal Investigator: Jorge R Almeida, MD, PhD Universidade Federal Fluminense
Layout table for additonal information
Responsible Party: Jorge R Almeida, MD, Professor, Universidade Federal Fluminense
ClinicalTrials.gov Identifier: NCT03114852    
Other Study ID Numbers: REGENT study
First Posted: April 14, 2017    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Urologic Diseases